A recent National Pharmaceutical Council (NPC) blog post offers highlights from a Feb. 28 webinar it hosted in collaboration with Discern Health. The online event aimed to outline some of the key points in a white paper, "Improving Patient-reported Measures in Oncology," published by the NPC and […]
Article: Germany as Model for Single-Payer System
A recent blog post in Health Affairs suggests looking to Germany as a model for transitioning to a single-payer landscape from a multipayer system. Pointing to presidential hopefuls floating single-payer and "Medicare for All" proposals, the authors say such initiatives face key hurdles. " ... The […]
Analysis: ICER Framework in Medicaid Could Threaten 820K Prescriptions
If Medicaid used the Institute for Clinical and Economic Review's (ICER) value framework, some 42-99 percent of prescriptions for serious conditions would be at risk of not being covered, a new analysis from Xcenda suggests. PhRMA in a blog post says those figures reveal "the dangerous effects […]
Boston Health Economics Offers Instant Health Data Platform
Boston Health Economics is offering direct access to HealthCore's HIRE-Oncology's clinical oncology data through its Instant Health Data (IHD) platform, according to an email from HealthCore. The platform, according to the email, offers clients streamlined access to data to bolster collaboration […]
Article: Taking on Low-Value Care is Key Issue
Tackling low-value care has become an increasingly important effort as some $340 billion is being spent on either low-value or unnecessary care, according to a Going Below the Surface post. An analysis of the Virginia All-Payer Claims Database by University of Michigan Center for Value-Based […]
HHS Receives 18,000 Comments on Drug Rebate Proposal
The Department of Health and Human Services has received some 18,000 comments on the Trump administration's proposal to end the current rebate model used to negotiate drug prices, STAT reports. According to the report, a large quantity of the submitted comments could have been the product of […]
Genesis Research, SIRIUS Market Access Announce New Partnership
Genesis Research and SIRIUS Market Access have partnered to deliver to clients a more robust service by offering a "comprehensive range of global HEOR, market access, and data analytics capabilities," according to a press release. Genesis, which was founded in 2009, brings to the table a "holistic […]
New #RxWritingChallenge Nears
The University of Minnesota is planning another #RxWritingChallenge for March 31- April 13. As part of the challenge, participants are urged to write at least 30 minutes Monday through Friday to "see how the practice of daily writing can enhance productivity," according to an email from challenge […]
Article on Drug Prices Spurs Debate
The authors of a recent article on drug prices published in Health Affairs have responded to criticisms levied by National Pharmaceutical Council CSO and Executive Vice President Robert Dubois, according to a STAT report. Dubois in a Health Affairs blog post criticized the paper for using list […]
ICER Releases Updated Protocol For Assessing Price Hikes
The Institute for Clinical and Economic Review (ICER) on Friday, March 15, released an updated protocol for its planned yearly analysis of drug price hikes to determine which are and aren't supported by clinical evidence. According to a press release, the first of these new reports is slated to […]
Legislators Target Anti-Competitive Practices
U.S. policymakers are looking to crack down on anti-competitive strategies some pharmaceutical companies use to delay the entry of generic competitors, according to a FierceHealthcare report. The House Committee on Energy and Commerce Health subcommittee on Wednesday discussed a host of bills […]
ICER Releases Draft Report on Siponimod
The Institute for Clinical and Economic Review (ICER) on Thursday, March 14, released a draft evidence report on Novartis's siponimod for the treatment of secondary progressive multiple sclerosis. According to a press release, the report is open to public comment until 5 p.m. EST April 10. ICER is […]
Article: FDA, Gottlieb Pushed on RWE
Food and Drug Administration (FDA) Commissioner Scott Gottlieb made a concentrated push on bringing real-world evidence into the fray, according to a Managed Care report. Gottlieb, who is set to resign next month, charged forward by issuing the FDA's real-world evidence framework in which it […]
RareChannels Taps Fortin as Chief Commercial Advisor
RareChannels on March 6 announced Lyne Fortin, a former Theratechnologies executive, would serve as the organization's chief commercial advisor. According to a release, Lyne brings 30-plus years of experience in the pharmaceutical industry. "When I began drawing out the leadership team wish-list, […]
PROs in Publication Planning?
Richard White, Oxford PharmaGenesis COO, in a recent article looks at how patient-reported outcomes (PROs) fit into publication planning. In his article, according to The Publication Plan, White backs a more broad scope in publication planning to incorporate all available evidence, be it economic, […]
Webinar to Spotlight Rising Out-of-Pocket Costs
AcademyHealth is set to host a March 20 webinar which will dive into a recent report by JPMorgan Chase on out-of-pocket health spending. The webinar is slated for 2:30-3:30 p.m. EST. JPMorgan's Fiona Greig will outline year-over-year trends for multiple demographics, according to the event […]
NICE META Tool Training Nears
The National Institute for Health and Care Excellence is planning to host a Medtech Early Technical Assessment (META) Tool training event April 2 in London. According to NICE's website, the fee to enter the training event is £500 ($667 USD). "Created by NICE Scientific Advice ... , the META Tool© […]
NPC’s Dubois: Article’s Authors ‘Used Flawed Data’
The authors of a recent article published in Health Affairs was using "flawed data" in their assessment of rising drug prices, National Pharmaceutical Council CSO and Executive Vice President Robert Dubois writes in a Health Affairs blog post. The data "likely [led] to flawed results," Dubois […]
Article: More Robust Regulations Needed to Wrangle Private Health Care
A recent article by economist Craig Garthwaite urges stronger regulations to address key problems in private health care, and that private organizations should "support efforts to fix competition ... ." "Our biggest policy mistakes result from writing poor regulations that either explicitly or […]
ISPOR to Host Webinar on MCDA for HTA Agencies
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is offering a webinar on the use of multi-criteria decision analysis (MCDA) for HTA agencies. Scheduled for 11 a.m. EST April 3, the online event will focus on how MCDA can be used to "improve the quality, consistency, […]
Congress Invites PBMs to Hearing
Moving forward with hearings on drug prices, the Senate Finance Committee has invited representatives from five pharmacy benefit managers to testify, Reuters reports. According to the report, the hearing is scheduled to take place April 3. Sens. Chuck Grassley and Ron Wyden this week sent invites […]
Study: Prescription Drug Spending Posted $90B Increase Between 2012-16
A new study by Pew Charitable Trusts found that prescription drug spending saw an almost $90 billion increase between 2012-16, surging to $341 billion in 2016 from $250.7 billion in 2012. The study found patients are paying more for prescription drugs, PBMs have passed on more pharma rebates to […]
Rutgers University’s Gusmano Talks Patient-Centered Care
Rutgers University professor Michael Gusmano discussed patient-centered care in a podcast posted March 6 on Health Affairs. Support is increasing for a system of health care built on patient-centered care, but the term "consumer" is being confused with term patient. Purchasing health care is not […]
Medicaid, Medicare Face Big Cuts
President Donald Trump's 2020 budget proposal includes significant cuts to Medicare and Medicaid, according to a Healthcare Dive report. The White House is looking to cut $845 billion from Medicare over the next decade, per the report, as well as move more than $1 trillion from Medicaid spending to […]
Trump Budget Includes Slew of Proposals to Cut Drug Prices
The Trump administration's budget proposal for 2020 features more than two dozen proposals aimed at reducing drug prices, according to an InsideHealthPolicy report. According to the report, the budget includes penalties for drugmakers that engage in anti-competitive practices, and bars companies […]
ICER White Paper Outlines Three Alternative Models for Pharma Rebates
A newly-released white paper by the Institute for Clinical and Economic (ICER), in partnership with the Office of Health Economics (OHE), offers a look at three potential alternative models for pharmaceutical rebates. The paper, "Value, Access, and Incentives for Innovation: Policy Perspectives on […]
NCI Director to Serve as Interim FDA Chief
National Cancer Institute Director Ned Sharpless has reportedly been tapped to serve as the Food and Drug Administration's interim chief, according to a FirstWord Pharma report. Sharpless will head the agency after FDA Commissioner Scott Gottlieb's resignation goes into effect next […]
U.S. in Line with Other Countries on Out-of-Pocket Costs
While the U.S. posts the highest numbers among similarly-developed countries for how much consumers pay for prescription drugs, it falls in line with those same countries on out-of-pocket costs, per an Axios report. The U.S. posted $1,016 in drug spending per capita in 2016, followed by Switzerland […]
NPC’s Graff Talks RWE’s Potential, Future
National Pharmaceutical Council (NPC) Vice President of Comparative Effectiveness Research Jennifer Graff during an interview with Managed Care said real-world evidence could be used consistently used in the next 10 years. "Whether this is ultimately a 10-year or 40-year evolution will be […]
AbbVie CEO Gonzalez Nets $21 Million
AbbVie CEO Richard Gonzalez reportedly brought home $21 million in 2018, according to a FiercePharma report, with almost $4 million of that coming from a performance-based incentive award. According to the report, Gonzalez's compensation is heavily tied with the success of the drugmaker's […]
